News Medical on MSN5d
Scientists analyze virus protein structure to advance RSV vaccines
In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) ...
GlobalData on MSN17h
ArkBio concludes dosing for RSV prevention trial in infants
Shanghai Ark Biopharmaceutical (ArkBio) has concluded enrolment and dosing for a Phase I trial of fully human monoclonal ...
cidrap.umn3d
US respiratory virus activity remains low ahead of holiday season
Respiratory virus activity remained low in the United States last week, with COVID levels continuing to decline, but ...
Medical Xpress7d
Experimental therapeutic reduces advanced-stage influenza viral loads faster than current therapies in preclinical study
The oral presentation "Novel Ligand-Targeted Immunotherapy for the Treatment of Human Respiratory Syncytial Virus (RSV)" ...
earth5d
How the COVID-19 virus travels deep inside our lungs
New COVID-19 research uncovers viral behavior insights, driving innovative treatments with Northwestern Medicine's support.
Science Daily6d
Eradivir's EV25 therapeutic reduces advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
A research article shows that Eradivir's patent-pending antiviral therapeutic called EV25 reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than ...
Macau Business1d
ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610,...
(“ArkBio”) announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a ...
Medscape10d
Nirsevimab Resistance Mutations Rare in RSV, Study Shows
Widespread distribution of nirsevimab to infants with respiratory syncytial virus infection raised concerns about potential ...